Results 51 to 60 of about 65,545 (257)
The Novel Oral Anticoagulants [PDF]
After the introduction of warfarin, long-term oral anticoagulation treatment remained unchanged for more than 50 years. Most recently, with the development and approval of new oral anticoagulants, the treatment of medical conditions that require thrombosis prophylaxis and long-term anticoagulation has become more complex.
Cristhiam M, Rojas-Hernandez +1 more
openaire +2 more sources
Fluorinated β‐glucan/pectin nanogels enable colon‐targeted oral delivery of astilbin through gastrointestinal protection, β‐glucanase‐responsive release, mucus penetration, and prolonged retention. The released astilbin attenuates senescence‐associated features of CD4+ T cells and promotes Treg responses, while the nanogel matrix modulates the gut ...
Lei Zhao +11 more
wiley +1 more source
Introduction Warfarin therapy is the mainstay of anticoagulation treatment in South Africa and requires frequent INR monitoring due to interindividual patient variability. Time in therapeutic range (TTR) reflects the proportion of total treatment time during which INR values are within therapeutic range.
Masudah Paleker +3 more
wiley +1 more source
In patients with atrial fibrillation, catheter ablation is suggested to reduce the mortality rate and is thus frequently performed. However, peri- and postprocedural thromboembolic complications as well as high recurrence rates of atrial fibrillation ...
Woon Hyung Chae +5 more
doaj +1 more source
Background Long‐acting intramuscular cabotegravir plus rilpivirine (LA‐CAB + RPV) is an effective maintenance antiretroviral regimen for virologically suppressed people with HIV. However, its use in individuals receiving chronic anticoagulation is limited by concerns regarding intramuscular bleeding risk, and real‐world data are scarce.
Montserrat Laguno +13 more
wiley +1 more source
Background This study assessed the sociodemographic, functional, and clinical determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation (NVAF) attended in the internal medicine setting.
Jose María Mostaza +5 more
doaj +1 more source
The optimal antithrombotic treatment in patients receiving oral anticoagulation undergoing percutaneous coronary intervention (PCI) has been a field of intensive research.
Despoina-Rafailia Benetou +3 more
doaj +1 more source
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou +10 more
wiley +1 more source
Background and objectives: Atrial fibrillation and flutter (AF/AFL) can be easily detected in patients who have a dual-chamber pacemaker (PM). This can result in a high detection rate of these arrhythmias especially if patients are monitored remotely and
Elias Parkkari +4 more
doaj +1 more source
The Mechanism of Action of Oral Anticoagulants and Its Consequences for the Practice of Oral Anticoagulation [PDF]
A short review on the discovery of the relation between vitamin K and the synthesis of clotting factors and on the development of anticoagulant therapy is given. The pro-coagulant activity induced by vitamin K resides in the postribosomal modification of N-terminal glutamic acids in γ-COOH glutamic acids.
Hemker, H.C., Frank, H.L.L.
openaire +3 more sources

